Tag Archives: finance

Confirmed Investors Attending RESI Europe 2026 — Early Bird Rates End Friday 

18 Feb

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to welcome investors from across the globe to RESI Europe 2026, taking place March 23 in Lisbon, Portugal, with virtual partnering scheduled for March 24–25 and 30–31. This premier event is designed to connect active early-stage investors with innovative life science companies and foster the partnerships that move promising science toward commercialization.

Early Bird rates expire this Friday, and those who register now will save €200. With partnering open March 2, this is the ideal time to secure your place and ensure access to the full RESI Europe experience.

RESI Europe convenes a highly engaged community of venture investors, corporate venture arms, family offices, strategic partners, and non-dilutive funding organizations, all actively evaluating new opportunities across therapeutics, diagnostics, medical devices, and digital health. The event is structured to maximize meaningful interactions, offering curated partnering, targeted networking, and direct visibility into emerging companies seeking capital and strategic collaboration.

For investors focused on sourcing new opportunities, building syndicates, and staying ahead of early-stage innovation trends, RESI Europe provides a concentrated and efficient environment to connect with founders, fellow investors, and ecosystem leaders from Europe, North America, and beyond. Conversations initiated at RESI frequently lead to follow-on diligence, partnerships, and investments that extend well beyond the event itself.

Confirmed RESI Europe Investors

Register before the Early Bird deadline this Friday to secure €200 in savings and confirm your participation alongside a growing global investor community.

Register for RESI Europe

Tags: , , , , , , , , , , , ,

Hot Investor Mandate: Early-Stage Venture Fund Seeks Data-Driven Diagnostics and Digital Health

18 Feb

Novalis Biotech is an early stage venture capital fund in life sciences. The firm’s investment ideas focus on the interaction between bio-informatics and life sciences. The firm strongly believes in applying innovative information technology to advance prevention, diagnosis, or treatment of diseases. Novalis focuses on capital light business models and platform technology. As an early stage private equity/venture capital fund, they are a dynamic and flexible player not restricting themselves to specific fields of expertise, but open to discuss any proposition in the field of life-sciences. The firm differentiates themselves by high dynamism and flexibility to rapidly evolve their portfolio companies. 
 
Novalis Biotech is interested in the diagnostics and digital health sectors. Within diagnostics, the firm is opportunistic and will consider technologies, services, and tools in development phases. Within digital health, the firm is opportunistic with interests including bioinformatics. The firm does not invest in clinical trials and will not consider traditional pharmaceuticals or medtech sectors. Indications of interest include oncology and neurology. 
 
Novalis Biotech highly values working with a top management team that is committed to the project. The firm acts as a lead investor and will require board seating. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Pre-Seed and Seed Stage VC Firm Backing AI and Next-Generation Computing in Healthcare

18 Feb

A pre-Seed and Seed-stage venture capital firm is focused on AI and next-generation computing technologies applied to large industries. The firm prefers to invest in companies located in North America.  

The firm partners with entrepreneurs addressing real-world problems through data and machine learning, with a focus on frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Prior investment areas have included biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, automated pathology solutions, and related technologies. 

From a company and management team perspective, the firm seeks experienced teams with a strong long-term vision. The firm may take a board seat when the firm brings specific domain expertise relevant to the company. The firm does not have a fixed equity ownership target. The firm values strong technical teams with deep market understanding and is comfortable partnering with very early-stage companies, including those at the pre-product stage. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Large Holding Company Manages Both Early and Late-Stage Focused Funds, Investing Up to $10-15M in Novel Therapeutics

18 Feb

A holding company manages an early-stage life sciences fund focused exclusively on private companies developing pharmaceutical products. The firm invests globally in early-stage programs, preferably with proof-of-concept validation, and supports companies from venture creation through Series A.  

Investments are made in the form of straight equity, with capital deployed over the life of the company. The firm is science-driven, may lead or co-invest, seeks board representation, and takes an active role in guiding company development and strategy. The firm does not target a fixed number of investments per year. 

In addition to the early-stage strategy, the firm also manages a late-stage vehicle focused on private pharmaceutical companies raising Series B through crossover or IPO rounds. 

Across both strategies, the firm is open to preclinical and clinical-stage therapeutic companies and is agnostic to modality and indication. The firm invests exclusively in first-in-class, breakthrough assets and does not consider repurposed drugs, diagnostics, medical devices, or incremental technologies. 

The firm prefers to invest early and support companies through major value inflection points. The firm does not impose specific requirements regarding management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Corporate VC Seeks Early-Stage Oncology Therapeutics & Platform Technologies in US and Europe

18 Feb

A strategic corporate venture capital fund makes equity investments in startup companies developing innovative therapeutic products and drug-enabling platform technologies with clear potential to benefit cancer patients. Investment size is flexible depending on the opportunity. In addition to traditional equity investments, the firm may consider option-based structures and spin-outs. The firm seeks opportunities primarily in US and Europe.  

The firm focuses on early-stage opportunities, generally from research through pre-IND, targeting first-in-class or new biology-based drug discovery approaches and innovative platform technologies. The firm prioritizes assets with strategic alignment to the parent organization’s pipeline. The firm evaluates a broad range of modalities, including biologics, oncolytic viruses, and small molecules, and considers cell and gene therapy on an opportunistic basis. The primary therapeutic focus is oncology, with additional interest in immunology, allergy, musculoskeletal, and orphan indications. 

While the firm is primarily therapeutics-focused, the firm may selectively review medical device, diagnostic, or digital health technologies where there is strong strategic alignment. 

From a company and management team perspective, the firm seeks teams with strong sector expertise. With the backing of an established oncology development organization, the firm provides financial support and facilitates strategic partnerships to help advance novel research and high-potential drug candidates toward commercialization. The firm may request regional options or rights on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Investor Fireside Chat in Barcelona: Building Momentum Toward RESI Europe  

10 Feb

By Brenda Olmos, Business Development Manager, Global Tech Hub and Sponsorship, LSN

In preparation for RESI Europe, the global life-science investment community will gather in Barcelona for an exclusive Investor Fireside Chat designed to equip founders and innovators with practical fundraising insights ahead of the conference.

Event Details
Date: February 18
Time: 15:00–19:00
Location: Hotel H10 Art Gallery, C/ Enric Granados 62, Barcelona

RSVP: https://form.jotform.com/260354367670157

This focused pre-RESI event brings together leading investors and pioneering entrepreneurs for an afternoon of strategy, storytelling, and networking within Barcelona’s vibrant innovation ecosystem.

Attendees will hear directly from investor Luis Pareras of InVivo Partners, joined by two standout founders shaping the future of neurotechnology and drug delivery: Ana Maiques of Neuroelectrics and Meritxell Teixidó of Gate2Brain. Together, they will share candid perspectives on what investors look for, how founders can position their companies effectively, and the realities of raising capital in today’s life-science landscape.

Speakers
Luis-Pareras Ana-Maiques Meritxell Teixidó
Luis ParerasFounder and Managing Partner
InVivo Partners		 Ana MaiquesCEO & CoFounder
Neuroelectrics		 Meritxell TeixidóCEO & CSO
Gate2Brain

The program will open with a hands-on Fundraising Bootcamp led by author and serial entrepreneur Dennis Ford (Boston), offering practical guidance on refining your pitch, navigating investor conversations, and building a compelling funding strategy. The session is designed to provide actionable takeaways that participants can immediately apply as they prepare for RESI Europe and beyond.

The afternoon will conclude with networking drinks, giving attendees the opportunity to connect with peers, investors, and ecosystem leaders in an informal setting.

Whether you are actively raising capital or planning your next financing round, this event offers a valuable opportunity to gain insight, build relationships, and align your strategy ahead of RESI Europe.

Register for RESI Europe

Tags: , , , , ,

Life Science Nation Names Dealflow.eu as a Title Sponsor of RESI Europe Lisbon; Highlights EIC Participation Pathway

10 Feb

By Greg Mannix, VP, EMEA Business Development, LSN

New collaboration strengthens access for European life science innovators to engage global capital investors and licensing partners

Cambridge, MA and Lisbon, Portugal 

Life Science Nation (LSN) announced today a partnership with Dealflow.eu, naming the organization as a Title Sponsor of RESI Europe Lisbon. The collaboration supports the identification and preparation of high-potential European life science innovators and strengthens pathways for companies—where eligible—to leverage European Innovation Council (EIC) reimbursement mechanisms to participate in the RESI partnering ecosystem.

Dealflow.eu operates as a European innovation matchmaking and readiness platform, surfacing high-potential life sciences and deep-tech companies and supporting their engagement with global investors and strategic partners. Through this collaboration, Dealflow.eu will route a curated cohort of life science companies to RESI Europe Lisbon, positioning them in front of a global audience of investors and partners actively seeking early-stage opportunities.

RESI Europe Lisbon serves as the global activation layer of the Life Science Nation partnering ecosystem, connecting emerging technologies with investors and strategic partners through curated matchmaking, investor panels, and the Innovator’s Pitch Challenge. Unlike broad innovation showcases, RESI is purpose-built for early-stage life sciences partnering and capital formation, enabling qualified investors and partners to engage with technologies prepared for global scrutiny.

As part of this collaboration, Dealflow.eu will support eligible companies in accessing available reimbursement mechanisms—such as those offered through EIC programs, where applicable—to offset a portion of RESI Europe registration costs. This helps reduce participation barriers and expands access for promising European life sciences innovators to connect with global capital and strategic partner networks.

“This partnership strengthens the pathway from early innovation to global partnering,” said Dennis Ford, Founder and CEO of Life Science Nation. “Dealflow.eu operates upstream, identifying and preparing high-potential innovators for investor engagement. RESI operates downstream, providing the global activation environment where capital investors and strategic partners connect with emerging technologies. At the same time, programs such as those offered through the EIC can help support company participation and readiness along that journey.”

“We see RESI Europe as a highly complementary activation platform for the Dealflow.eu network,” said André Moraes Sarmento, Dealflow.eu. “Our mission is to connect high-potential innovators with investors, corporates, and strategic partners. This collaboration gives life science companies direct access to a global audience of qualified investors and licensing partners actively seeking early-stage technologies.”

The collaboration also includes coordinated programming at RESI Europe Lisbon, dedicated visibility opportunities for participating innovators, pre-conference preparation support, and continued alignment to strengthen pathways from European innovation to global market engagement.

RESI Europe Lisbon will take place in Lisbon, Portugal, bringing together global investors, strategic partners, and early-stage life sciences innovators across therapeutics, devices, diagnostics, digital health, and enabling technologies.

About Life Science Nation

Life Science Nation operates a global partnering and matching ecosystem that connects early-stage life sciences companies with qualified capital investors and licensing partners worldwide. Its platforms include the RESI Conference Series, LSN Labs entrepreneurial education and readiness programs, and global partnering campaign infrastructure.

About Dealflow.eu

Dealflow.eu is a European innovation matchmaking and readiness platform connecting high-potential innovators with investors, corporates, and strategic partners across Europe and globally.

Media Contact
Caitlin Dolegowski
Marketing Manager
Life Science Nation
c.dolegowski@lifesciencenatio.com
719-229-9290

Tags: , , , , , , , , , ,

← Older Entries